Resources

From 2018-2022, the Devices, Diagnostics, and Drugs to AddressWomen’s Needs (D3AWN) Product Development Partnership (PDP)program advanced a portfolio of four products for the prevention andmanagement of postpartum hemorrhage (PPH) and preeclampsia/eclampsia (PE/E) in African markets: the Ellavi uterine balloontamponade (UBT), LifeAssay Test-it™ protein-to-creatinine (PrCr)Urinalysis Dipstick Test, RELI Delivery system, and oxytocin insublingual fast-dissolving tablet formulation.

This brief aims to provide an overview of point-of-care (POC) glucose-6-phosphate dehydrogenase (G6PD) diagnostics and to point readers in the direction of additional in-depth resources. The content below explains why G6PD testing is necessary, how G6PD status is classified and measured, which diagnostics are commercially available and what studies have been conducted with them, and considerations for successfully adopting G6PD testing. The audiences that may find this brief most useful are national malaria program staff, malaria project implementers, and others seeking a high-level understanding of G6PD diagnostics that could be used in malaria elimination efforts. The information contained within this document was accurate to our knowledge at the time of publication, but please bear in mind that this is a fast-moving field of emerging evidence.

Since 1980, PATH has been working alongside leaders, communities, and local change makers to develop sustainable systems for tackling shifting health challenges in Vietnam, Laos, Indonesia, Cambodia, and the Philippines.

Since 1980, PATH has been working alongside leaders, communities, and local change makers to develop sustainable systems for tackling shifting health challenges in Vietnam, Laos, Indonesia, Cambodia, and the Philippines.

Febrile illness, pneumonia, and anaemia each have multiple etiological origins, present with overlapping symptoms, and often are diagnosed by low-skilled frontline health care workers with insufficient or inadequate tools and high patient loads. Furthermore, health care workers in low-resource settings rely on clinical signs to triage these conditions, despite known issues with the accuracy and reliability of these methods, which results in patients being misdiagnosed and not receiving appropriate care. Providing health care workers with tools to help them identify the signs of severe illness could help overcome these challenges.Multimodal (or next generation) pulse oximeters —noninvasive handheld devices that expand the features of standard handheld pulse oximeters by additionally measuring respiratory rate, temperature, and/or hemoglobin—are a promising technology that can provide objective measurements to support clinical decision-making. Combining more than one clinical measurement into a multimodal pulse oximeter has the potential to improve the accuracy and efficiency of, as well as adherence to, consultations that facilitate more appropriate diagnosis and integrated management of illnesses. In addition to reducing mortality, multimodal pulse oximeters could further enhance efficient use of resources and reduce the overall strain on the health system by minimizing the need for costly testing, strengthening referral decisions, and reducing unnecessary hospitalizations, intensive therapy, and overuse of antibiotic treatments.This report aims to assess the potential of multimodal pulse oximeters to improve the integrated diagnosis and treatment of illnesses for patients presenting at health facilities in low- and middle-income countries, with a focus on maternal and child health applications. Understanding technological challenges, existing and pipeline products, and market challenges is key for facilitating equitable access to these tools through market-based interventions.